The Global Exchange States Its Case
Executive SummaryGlobal Exchange was set up last winter by five of the largest med-surg companies to make sure they had a role in shaping the future of e-commerce and hospitals. For several months it was reticent but now its new general manager is explaining its mission to provide a single centralized portal for e-procurement to hospitals and integrated delivery systems that results in greater efficiency and savings for hospitals. A major reason for its formation was the concern that established, private-investor-led dot.coms, such as Medibuy and Neoforma.com, were trying to squeeze manufacturers. But the Global Exchange raised concerns among the very manufacturers it was set up to protect--for example, how it would handle competitors and whether each member get the same terms as the others. The exchange has five founding partners, but it is open to all, and all suppliers pay a subscription fee, based on the volume of business they do through the exchange. So far, 40 hospitals have signed up to use the system, which will go on line this fall and the system offers more than 60% of all med-surg supplies on the market. While dot.coms have taken a beating in the stock market in recent months, the Global Health Exchange says it isn't beholden to Wall Street because it has no plans to go public. It is in this business for the long-term, despite the ups and downs of competitors.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.